<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:aavptbiennial-ojs-tamu.tdl.org:article/94</identifier>
				<datestamp>2024-10-30T18:33:57Z</datestamp>
				<setSpec>aavptbiennial:S2</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Good Laboratory Practices Regulations: Implications for Veterinary Pharmacology and Therapeutics</dc:title>
	<dc:creator xml:lang="en">Norcross, Marvin A.</dc:creator>
	<dc:subject xml:lang="en">Food and Drug Administration</dc:subject>
	<dc:subject xml:lang="en">FDA</dc:subject>
	<dc:subject xml:lang="en">veterinary pharmacology.</dc:subject>
	<dc:subject xml:lang="en">Bioresearch Monitoring Program</dc:subject>
	<dc:description xml:lang="en">On March 7, 1978, Commissioner Donald Kennedy appeared before a Senate Sub-Committee chaired by Edward M. Kennedy (D-Mass) and described some of the abuses known to the Food and Drug Administration (FDA) in the area of human clinical research. (1) These abuses, which were called by Senator Kennedy a 11 perversion of science", ranged from physicians misrepresenting studies to patients while obtaining their informed consent to counting fictitious subjects as active participants in clinical studies. This hearing is reminiscent of earlier hearings in which FDA presented data concerning the deficiencies observed in toxicological studies performed in support of drug applications submitted to the Agency. These hearings resulted in an initiative in FDA known as the Bioresearch Monitoring Program.
It is my purpose to present some of the history, the current status and the implications this program, especially good laboratory practices, has on veterinary pharmacology.</dc:description>
	<dc:publisher xml:lang="en">AAVPT Biennial Symposia</dc:publisher>
	<dc:date>1978-03-13</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/94</dc:identifier>
	<dc:source xml:lang="en">AAVPT Biennial Symposia; First Symposium; 124-138</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://aavptbiennial-ojs-tamu.tdl.org/aavptbiennial/article/view/94/88</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1978 American Academy of Veterinary Pharmacology and Therapeutics</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
